TCON - トラコン・ファ―マシュ―ティカルズ （TRACON Pharmaceuticals Inc.）

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON – Get Rating) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 161,000 shares, a decline of 38.7% from the April 30th total of 262,500 shares. Based on an average daily trading volume, of 181,900 shares, […]

https://www.investing.com/news/pro/tracon-pharmaceuticals-inc-receives-investment-bank-analyst-rating-update-3079941

TRACON Pharmaceuticals, Inc. (NASDAQ:NASDAQ:TCON) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ETCompany ParticipantsCharles Theuer - CEO, President & DirectorScott Brown -…

TRACON Pharma (NASDAQ: TCON ) reported its Q1 earnings results on Wednesday, May 10, 2023 at 04:02 PM. Here''s what investors need to know about the announcement. Earnings TRACON Pharma missed estimated earnings by 38.46%, reporting an … Full story available on Benzinga.com

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

The Dow Jones closed higher by more than 250 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. NN The Trade: NN, Inc. (NASDAQ: NNBR ) 10% owner Hjalmar Eric Soderlund acquired a total 95,053 shares an average price of $1.04. To acquire these shares, it cost around $98.76 thousand. What’s Happening: NN opened a state-of-the-art 50,000+ square foot facility in São Paulo, Brazil. What NN … Full story available on Benzinga.com

… of its arbitration with Tracon Pharmaceuticals (Tracon) relating to (1) the …

I-Mab (NASDAQ:IMAB) recently went through an arbitration tribunal with Tracon Pharmaceuticals (NASDAQ:TCON) over a couple of collaboration agreemen…

Baudax Bio (BXRX) +48%. Petros Pharmaceuticals (PTPI) +48%. Tracon Pharmaceuticals (TCON) -43%. Maia Biotechnology (MAIA) -21%.

Nikola (NASDAQ: NKLA ) stock is getting a boost on Tuesday following news that the EV company is expanding its business to Canada . According to a press release from the EV company, it’s expanded into Alberta, Canada with the sale of a Nikola Tre battery-electric vehicle (BEV) and a Nikola Tre hydrogen fuel cell electric vehicle (FCEV). These were sold to the Alberta Motor Transport Association (AMTA). AMTA intends to introduce these vehicles in its Hydrogen Commercial Vehicle Demonstrations Project. The organization has also secured the refueling support needed for them from Nikola. Doug Paisley, Board chair at AMTA, said the following about the purchase. “We are excited to put these Nikola trucks to work in Alberta and begin collecting performance data, raising awareness to this advanced technology, promoting early adoption, and creating industry confidence in such an innovative technology.” What This Means For NKLA Stock Investors are excited about what this news means for NKLA stock.

In the last trading session, 81865.0 shares of the TRACON Pharmaceuticals Inc. (NASDAQ:TCON) were traded, and its beta was 1.35. Most recently the company’s share price was $1.78, and it changed around $0.02 or 1.31% from the last close, which brings the market valuation of the company to $39.10M. TCON currently trades at a discount … TRACON Pharmaceuticals Inc. (NASDAQ: TCON) Stock Forecast: Bullish Signals Pointing To $14.00 In 2023 Read More »

As of Tuesday, TRACON Pharmaceuticals Inc.’s (NASDAQ:TCON) stock closed at $1.44, up from $1.30 the previous day. While TRACON Pharmaceuticals Inc. has overperformed by 10.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TCON fell by -50.52%, with highs and lows ranging from $3.30 to $1.10, […]

TRACON Pharmaceuticals (TCON) announced entry into an up to $30M non-recourse financing agreement.$3.5M will be funded before December 31, 2022

Initial $3.5M Funding Maintains Cash Runway of Mid-2023 Initial $3.5M Funding Maintains Cash Runway of Mid-2023

TRACON Pharmaceuticals had its price objective cut by Robert W. Baird from $10.00 to $8.00 in a research report sent to investors on Thursday morning, The Fly reports…